[Parenteral methotrexate in patients with rheumatoid arthritis: systematic review, crossectional study and economic evaluation]
Brodszky V, Pentek M, Karpati K, Gulacsi L
Record ID 32010001763
Hungarian, English
Authors' recommendations:
Metoject is an effective treatment for RA compared to placebo in terms of improving symptoms and preventing radiological damage. Efficacy of the parenteral administration of methotrexate is superior to per os treatment due to the higher bioavailability, and lower rate of side effects, including gastrointestinal symptoms. There is no significant difference in the clinical efficacy and safety figures of the methotrexate and leflunomid therapy. Our results shows that the likelihood of successful therapy is higher with Metoject administration and parenteral methotrexate should be given before biological therapy, when applicable.
Details
Project Status:
Completed
Year Published:
2007
URL for published report:
http://hecon.uni-corvinus.hu/download/english/publ/hecon_research_24_eng.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Hungary
MeSH Terms
- Antirheumatic Agents
- Methotrexate
Contact
Organisation Name:
Unit of Health Economics and Technology Assessment in Health Care
Contact Address:
Unit of Health Economics and Technology Assessment in Health Care Department of Public Policy and Management Budapest University of Economic Studies 1125 Budapest Fovam ter 8 Budapest HUNGARY Tel: +36 1 218 8197 Fax: +36 1 218 1466
Contact Name:
laszlo.gulacsi@uni-corvinus.hu
Contact Email:
laszlo.gulacsi@uni-corvinus.hu
Copyright:
Unit of Health Economics and Technology Assessment in Health Care (HunHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.